CARMAT (FR0010907956, ALCAR), designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the “CARMAT”), provides an update on Aeson® artificial heart’s uptake as a bridge to transplant in Europe.
Aslan touts data for competitor to Dupixent as it seeks new partners
Aslan Pharmaceuticals said Thursday morning that its experimental drug for eczema, or atopic dermatitis, helped more patients achieve nearly clear or clear skin compared to